These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26015411)

  • 1. Safety, virology and pharmacokinetics of oseltamivir in infants with laboratory-confirmed influenza: a Phase I/II, prospective, open-label, multicentre clinical trial.
    Rath BA; Brzostek J; Guillén S; Niranjan V; Chappey C; Rayner CR; Clinch B
    Antivir Ther; 2015; 20(8):815-25. PubMed ID: 26015411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studies.
    Muñoz FM; Anderson EJ; Deville JG; Clinch B; Kamal MA
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):531-40. PubMed ID: 26042486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective surveillance of antiviral resistance in hospitalized infants less than 12 months of age with A(H3N2) influenza infection and treated with oseltamivir.
    Rath B; Chen X; Spies V; Muehlhans S; Obermeier P; Tief F; Seeber L; Karsch K; Milde J; Skopnik H; Schweiger B; Duwe SC
    Antivir Ther; 2017; 22(6):515-522. PubMed ID: 28205506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults.
    Ison MG; Hui DS; Clezy K; O'Neil BJ; Flynt A; Collis PJ; Simon TJ; Alexander WJ
    Antivir Ther; 2013; 18(5):651-61. PubMed ID: 23111657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir.
    Kawai N; Ikematsu H; Iwaki N; Kawashima T; Maeda T; Mitsuoka S; Kondou K; Satoh I; Miyachi K; Yamaga S; Shigematsu T; Hirotsu N; Kashiwagi S
    J Infect; 2007 Sep; 55(3):267-72. PubMed ID: 17604839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survey of Japanese infants younger than 3 months who were treated with oseltamivir for influenza: safety of oseltamivir treatment.
    Morioka I; Nonoyama S; Tanaka-Taya K; Ihara T; Sugaya N; Ueta I; Kumagai T; Okada K; Hosoya M; Okabe N; Morishima T;
    Scand J Infect Dis; 2012 Aug; 44(8):605-9. PubMed ID: 22497443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features, oseltamivir treatment and outcome in infants aged <12 months with laboratory-confirmed influenza A in 2009.
    Khandaker G; Zurynski Y; Lester-Smith D; Kesson A; Heron L; Dwyer DE; Elliott EJ; Booy R
    Antivir Ther; 2011; 16(7):1005-10. PubMed ID: 22024516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A part-randomized study of intravenous oseltamivir in adolescents and adults.
    Várkonyi I; Chappey C; Giraudon M; Burleigh L
    Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1181-8. PubMed ID: 25678009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.
    Beigel JH; Bao Y; Beeler J; Manosuthi W; Slandzicki A; Dar SM; Panuto J; Beasley RL; Perez-Patrigeon S; Suwanpimolkul G; Losso MH; McClure N; Bozzolo DR; Myers C; Holley HP; Hoopes J; Lane HC; Hughes MD; Davey RT;
    Lancet Infect Dis; 2017 Dec; 17(12):1255-1265. PubMed ID: 28958678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial.
    Wang C; Cao B; Liu QQ; Zou ZQ; Liang ZA; Gu L; Dong JP; Liang LR; Li XW; Hu K; He XS; Sun YH; An Y; Yang T; Cao ZX; Guo YM; Wen XM; Wang YG; Liu YL; Jiang LD
    Ann Intern Med; 2011 Aug; 155(4):217-25. PubMed ID: 21844547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS).
    Whitley RJ; Boucher CA; Lina B; Nguyen-Van-Tam JS; Osterhaus A; Schutten M; Monto AS
    Clin Infect Dis; 2013 May; 56(9):1197-205. PubMed ID: 23307766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial.
    Finberg RW; Lanno R; Anderson D; Fleischhackl R; van Duijnhoven W; Kauffman RS; Kosoglou T; Vingerhoets J; Leopold L
    J Infect Dis; 2019 Mar; 219(7):1026-1034. PubMed ID: 30428049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virus load kinetics and resistance development during oseltamivir treatment in infants and children infected with Influenza A(H1N1) 2009 and Influenza B viruses.
    Rath B; von Kleist M; Tief F; Karsch K; Tuerk E; Muehlhans S; Louis F; Skopnik H; Schweiger B; Duwe S
    Pediatr Infect Dis J; 2012 Sep; 31(9):899-905. PubMed ID: 22581220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential influenza B viral load and susceptibility in children treated with oseltamivir and zanamivir.
    Sato M; Honzumi K; Sato T; Hashimoto K; Watanabe M; Miyazaki K; Kawasaki Y; Hosoya M
    Pediatr Infect Dis J; 2014 Jul; 33(7):e168-72. PubMed ID: 24445826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral shedding and susceptibility to oseltamivir in hospitalized immunocompromised patients with influenza in the Influenza Resistance Information Study (IRIS).
    Fraaij PL; Schutten M; Javouhey E; Burleigh L; Outlaw R; Kumar D; Boucher CA
    Antivir Ther; 2015; 20(6):633-42. PubMed ID: 25849228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections.
    Lee N; Hui DS; Zuo Z; Ngai KL; Lui GC; Wo SK; Tam WW; Chan MC; Wong BC; Wong RY; Choi KW; Sin WW; Lee EL; Tomlinson B; Hayden FG; Chan PK
    Clin Infect Dis; 2013 Dec; 57(11):1511-9. PubMed ID: 24046309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective observational study of oseltamivir safety and tolerability in infants and young children ≤24 months.
    Rath BA; Blumentals WA; Miller MK; Starzyk K; Tetiurka B; Wollenhaupt M
    Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):286-96. PubMed ID: 25331369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.
    Oo C; Barrett J; Hill G; Mann J; Dorr A; Dutkowski R; Ward P
    Paediatr Drugs; 2001; 3(3):229-36. PubMed ID: 11310719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled trial evaluating the safety of early oseltamivir treatment among children 0-9 years of age hospitalized with influenza in El Salvador and Panama.
    Dawood FS; Jara J; Gonzalez R; Castillo JM; De León T; Estripeaut D; Luciani K; Sujey Brizuela Y; Barahona A; Cazares RA; Lawson AM; Rodriguez M; de Viana D; Franco D; Castillo M; Fry AM; Gubareva L; Tamura D; Hughes M; Gargiullo P; Clara W; Azziz-Baumgartner E; Widdowson MA
    Antiviral Res; 2016 Sep; 133():85-94. PubMed ID: 27451343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.